Načítá se...
Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics
Resistance of malignant glioma, including glioblastoma (GBM), to the chemotherapeutic temozolomide (TMZ) remains a key obstacle in treatment strategies. The gap junction protein connexin43 (Cx43) has complex roles in the establishment, progression, and persistence of malignant glioma. Recent finding...
Uloženo v:
| Vydáno v: | Curr Opin Pharmacol |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6292445/ https://ncbi.nlm.nih.gov/pubmed/29803991 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.coph.2018.05.002 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|